Solvay

Caught on the wrong foot

24/06/20 -"Solvay’s €1.5bn impairment of the back of the current challenging business situation is the price the current management has to pay for the predecessor’s expensive decisions. The ..."

PDF page sample
Pages
60
Language
English
Published on
24/06/20
Download
You may also be interested by these reports :
14/10/26
2026E: We raise our H2 2026 estimates, with our view that earnings will be driven primarily by pricing. We expect Q3 to broadly replicate Q2 2026, ...
13/10/26
Givaudan delivered a strong quarter, reaffirming its leading position in fragrances. Fine Fragrance continues to resist the normalisation anticipated ...
07/10/26
2026E: The reduction in our EPS estimate mainly reflects a more cautious view on potash prices in H2 2026, compounded by likely higher freight costs. ...
07/10/26
The FT reports that the European Commission’s pesticide omnibus, which partly mirrors industry lobbying, intends to make approvals unlimited, ease ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO